MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney ...

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord ...

Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created ...

Kancera AB (publ) today announces the decision to focus its business on developing the company’s fractalkine blocking candidate drugs KAND567 and KAND145 to treat cardiovascular diseases, initially ...

Experienced diabetologist and medical director, Dr. Owen brings to DiogenX over two decades of expertise in diabetes clinical management and drug development, as lead candidate progresses towards ...

Month figures/Quarterly / Interim StatementMedios AG reports record quarter Q3 2024 with significant increase in earnings and margins (news with additional features)12.11.2024 / 08:41 CET/CESTThe ...

AEVIS VICTORIA SA (AEVIS) achieved total revenues of CHF 761.0 million as at 30 September 2024, an increase of 7.1% compared to CHF 710.2 million in 2023. On a comparable basis, organic revenue growth ...

ExpansionLonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST The expansion of bioconjugation capabilities will provide additional ...

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), reached another milestone on ...

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s ...

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of ...

STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug, ...